{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:26:57Z","timestamp":1760783217428},"reference-count":35,"publisher":"Wiley","issue":"S123","license":[{"start":{"date-parts":[[2011,1,11]],"date-time":"2011-01-11T00:00:00Z","timestamp":1294704000000},"content-version":"vor","delay-in-days":9872,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Obstet Gynecol Scand"],"published-print":{"date-parts":[[1984,1]]},"abstract":"<jats:p><jats:bold>Abstract. <\/jats:bold> The purpose of the investigation was to study various aspects of danazol treatment in patients with fibro\u2010cystic breast disease and pronounced mastodynia. To qualify for inclusion, the patients in this study had to have a mammographically confirmed prominent glandular structure and\/or severe cystic breast disease, associated with pronounced cyclical mastodynia lasting at least one week per menstrual bycle for more than 6 months. They also had to be premenopausal and not undergoing hormonal therapy.<\/jats:p><jats:p>Of 109 patients with a mean age of 40\u00b16.2 (SD) years, who completed 6 months' treatment with danazol, 65% had a pre\u2010treatment history of more than 5 years. According to detailed mammographic characterization, only 18% of the patients had no visible cysts. Of the 82% with visible cysts, half presented with both small (&lt; 1 cm) and large cysts. The patients were treated in two consecutive groups, 55 patients receiving 400 mg a day and 54 patients 200 mg a day.<\/jats:p><jats:p>The therapeutic response was similar following both dosages. Mastodynia responded rapidly and total elimination was noted in about 90% of cases. A marked decrease in prominence of palpable structure was observed in virtually all patients. Mammographically, a decrease in the amount of glandular tissue was observed. These changes during treatment were statistically highly significant (p&lt;0.001), irrespective of dose or category of patient. Non\u2010cystic nodularities gradually decreased in 85% and resolved completely in 58% of the cases, but the degree of resolution in the groups of patients with no or only small (&lt; 1 cm) visible cysts was significantly greater (p &lt; 0.02 or less) than in the group which also had large cysts and which included the most severe and intractable cases.<\/jats:p><jats:p>The mammographical visualization of cysts, ductal system, and fibrous tissue increased initially due to the marked regression of obscuring glandular tissue. Thereafter, a decrease in the number and spread of small cysts was observed in a significant proportion of patients and in some cases a reduction in duct diameter could be demonstrated by means of galactography. Nipple discharge also decreased. The extent of fibrosis appeared to be unaffected by therapy. In the 46 patients with large cysts and, in most cases, a documented history of repeated cyst formation, danazol treatment was found to arrest the development of new cysts and to, Fibrocystic breast disease, mammographic evaluation of treatment, cyst formation, post\u2010treatment relapse, danazol treatment was found to arrest the development of new cysts and to prevent recurrence for a considerable time thereafter. Within 2\u00bd years of treatment, only 9 patients had recurrence of large cysts and even in these cases the rate of cyst formation was less than half of the pre\u2010treatment rate.<\/jats:p><jats:p>Menstrual irregularities or amenorrhea were noted in 66 and 85010 during danazol treatment with 200 and 400 mg, respectively. A moderate weight gain of approximately 2 kg was the most common side effect. Other side effects were not infrequent, but usually well tolerated, particularly at the 200 mg daily dose. In no case was there any need to stop treatment on medical grounds and laboratory safety monitoring did not reveal consistent changes.<\/jats:p><jats:p>During a post\u2010treatment observation period of up to 3 years, the patients were followed with regard to symptomatic relapse, defined as recurrent mastodynia of similar intensity as before treatment in still premenopausal women. In patients treated with 200 mg, the cumulative relapse rate was 67% during a mean observation period of 18.2 months, with a mean interval to relapse of 9.2 months. In patients treated with 400 mg, the cumulative relapse rate was 52% within a mean period of 27. I months and a mean interval to relapse of 12.2 months.<\/jats:p><jats:p>Clinical and, in particular, mammographic findings point to an involution and apparent inactivation of glandular tissue as the key to the therapeutic action of danazol in the treatment of fibrocystic breast disease, affecting not only subjective symptoms, but also causing profound changes in mammographic structure and activity, as evidenced by arrested cyst formation.<\/jats:p>","DOI":"10.3109\/00016348409157006","type":"journal-article","created":{"date-parts":[[2009,12,8]],"date-time":"2009-12-08T17:58:18Z","timestamp":1260295098000},"page":"159-176","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Danazol treatment of severely symptomatic fibrocystic breast disease and long\u2010term follow\u2010up\u2014the Hj\u00f8rring project"],"prefix":"10.1111","volume":"63","author":[{"given":"Tobias","family":"Tobiassen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorkild","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"D\u00f6berl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Rannevik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,1,11]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"181","article-title":"Treatment of benign breast disease with danazol: A follow\u2010up report","volume":"21","author":"Aksu M. F.","year":"1978","journal-title":"J Reprod Med"},{"key":"e_1_2_1_3_1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/0002-9378(80)91054-6","article-title":"Mechanism of induction of luteal phase defects by danazol","volume":"136","author":"Asch R. H.","year":"1980","journal-title":"Am J Obstet Gynecol"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(16)33237-9"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)43820-3"},{"issue":"3","key":"e_1_2_1_6_1","first-page":"101","article-title":"Danazol in the treatment of benign breast disease","volume":"5","author":"Blackmore W. P.","year":"1977","journal-title":"J Int Med Res"},{"key":"e_1_2_1_7_1","unstructured":"BlackmoreW. P..Results of the clinical evaluation of danazol in fibrocystic breast disease. Paper read at a Symposium on Fibrocystic Breast Disease Washington D. C. May 1979."},{"issue":"5","key":"e_1_2_1_8_1","first-page":"52","article-title":"Danazol treatment in benign breast disease: A survey of U. S. A. multicentre studies","volume":"55","author":"Brookshaw J. D.","year":"1979","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016348409157005"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016348409156998"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(80)90665-1"},{"issue":"1","key":"e_1_2_1_12_1","first-page":"66","article-title":"Danazol treatment of chronic cystic mastopathy: A clinical and hormonal evaluation","volume":"55","author":"Dhont M.","year":"1979","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)46757-9"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016348409157007"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016348409156997"},{"key":"e_1_2_1_16_1","unstructured":"GreenblattR. B..Danazol and fibrocystic breast disease: Results of clinical evaluation in Georgia. Paper read at a Symposium on Fibrocystic Breast Disease Washington D. C. May 1979."},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)44955-1"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)44722-9"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)45446-4"},{"key":"e_1_2_1_20_1","first-page":"93","article-title":"The effect of danazol in the treatment of chronic cystic mastitis","volume":"48","author":"Lauersen N. H.","year":"1976","journal-title":"Obstet Gynecol"},{"key":"e_1_2_1_21_1","first-page":"719","article-title":"A comparison of plasma protein changes induced by danazol, pregnancy, and estrogens","volume":"49","author":"Laurell C B.","year":"1979","journal-title":"J C E M"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)91932-8"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(80)90683-3"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(80)90704-8"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016348409156992"},{"key":"e_1_2_1_26_1","first-page":"159","article-title":"Effect of danazol on the radiographic density of breast parenchyma","volume":"32","author":"Ouimet\u2010Oliva D.","year":"1981","journal-title":"J Canad Ass Radiol"},{"key":"e_1_2_1_27_1","first-page":"595","article-title":"Klinische Erfahrungen mit Danazoltherapie bei Endometriose und Mastopathie","volume":"93","author":"Pavelka R.","year":"1981","journal-title":"Wr Klin Wschr"},{"key":"e_1_2_1_28_1","first-page":"69","article-title":"Transport of steroid hormones: Interaction of 70 drugs with testosterone\u2010binding globulin and corticosteroid\u2010binding globulin in human plasma","volume":"53","author":"Pugeat M. M.","year":"1981","journal-title":"J C E M"},{"issue":"5","key":"e_1_2_1_29_1","first-page":"14","article-title":"Hormonal, metabolic and clinical effects of danazol in the treatment of endometriosis","volume":"55","author":"Rannevik G.","year":"1979","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_30_1","first-page":"127","volume-title":"Endocrinology of Cystic Breast Disease","author":"Rannevik G.","year":"1983"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016348409156990"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016348409157004"},{"key":"e_1_2_1_33_1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0015-0282(16)43336-4","article-title":"Pituitary gonadotropin responsiveness with danazol","volume":"29","author":"Shane J. M.","year":"1978","journal-title":"Fertil Steril"},{"key":"e_1_2_1_34_1","unstructured":"StraxP..Danazol and fibrocystic breast disease: Results of clinical evaluation at the Guttman Institute New York City. Paper read at a Symposium on Fibrocystic Breast Disease Washington D. C. May 1979."},{"key":"e_1_2_1_35_1","first-page":"190","article-title":"Mechanism of antiprogestational action of synthetic steroids","volume":"88","author":"Tamaya T.","year":"1978","journal-title":"Acta Endocr"},{"issue":"5","key":"e_1_2_1_36_1","first-page":"33","article-title":"Effect of danazol on thyroid function in women","volume":"55","author":"Thorell J. I.","year":"1979","journal-title":"Postgrad Med J"}],"container-title":["Acta Obstetricia et Gynecologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.3109%2F00016348409157006","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.3109\/00016348409157006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T23:20:11Z","timestamp":1697757611000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.3109\/00016348409157006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,1]]},"references-count":35,"journal-issue":{"issue":"S123","published-print":{"date-parts":[[1984,1]]}},"alternative-id":["10.3109\/00016348409157006"],"URL":"https:\/\/doi.org\/10.3109\/00016348409157006","archive":["Portico"],"relation":{},"ISSN":["0001-6349","1600-0412"],"issn-type":[{"value":"0001-6349","type":"print"},{"value":"1600-0412","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,1]]},"assertion":[{"value":"2011-01-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}